Efficacy and safety of dulaglutide in patients with type 2 diabetes and obesity
https://doi.org/10.62751/2713-0177-2025-6-3-02
Abstract
The aim: to evaluate the effect of dulaglutide on metabolic markers and body composition in patients with type 2 diabetes mellitus (T2DM) and obesity.
Material and methods. A randomized interventional study was conducted. The study involved: a study group of 57 people with T2DM, obesity of varying severity, who added dulaglutide 1.5 mg once a week to metformin therapy. The control group consisted of 53 patients on metformin monotherapy at a dose of 1.5–2.0/day. All patients underwent an examination at the beginning and after a year of therapy, which included the determination of glycemic control parameters (glycated hemoglobin, fasting blood glucose), anthropometric parameters (body weight, body mass index (BMI), waist circumference (WC)), irisin, highly sensitive C-reactive protein (HCRP), body composition with using bioimpedance measurement.
Results. After one year of therapy, the addition of dulaglutide led to a statistically significant decrease in the level of glycated hemoglobin from 7.2 [6.5; 9.3] to 6.5 [6.2; 8.4] % (p <0.05), body weight – from 109 [93–131] to 105 [65–129] kg (p <0.05), BMI – from 39.2 to 37.05 kg/m2 (p <0.05), WC – from 125 [115–135] to 119 [91–127] cm (p <0.05). In addition, the addition of dulaglutide to therapy led to a statistically significant increase in irisin from 4.01 [2.39–6.73] to 5.33 [1.46–8.38] ng/ml (p <0.05), there was also a significant decrease in HCRP, a decrease in adipose tissue mass according to the results of bioimpedance.
Conclusion. The intensification of therapy by adding dulaglutide once a week to metformin therapy in patients with T2DM and obesity contributed to a statistically significant improvement in glycemic control, a marker of inflammation, increased irisin, and a decrease in the amount of adipose tissue, while there was no decrease in musculoskeletal mass.
About the Authors
D. G. Gusenbekova
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Dinara G. Gusenbekova – C. Sci. (Med.), Associate Professor, Department of Therapy and Polymorbid Pathology named after academician M.S. Vovsi, Russian Medical Academy of Continuous Professional Education; endocrinologist at City Polyclinic No. 219
Moscow
A. S. Ametov
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Alexander S. Ametov – D. Sci. (Med.), Head of the Department of Endocrinology
Moscow
T. N. Korotkova
Federal Research Center for Nutrition, Biotechnology and Food Safety
Tatiana N. Korotkova – C. Sci. (Med.), Head of the Laboratory of Clinical Biochemistry, Allergology and Immunology
Moscow
References
1. Pacifico J, Geerlings MAJ, Reijnierse EM, Phassouliotis C, Lim WK, Maier AB. Prevalence of sarcopenia as a comorbid disease: A systematic review and metaanalysis. Exp Gerontol. 2020;131:110801. doi: 10.1016/j.exger.2019.110801.
2. Anagnostis P, Gkekas NK, Achilla C, Pananastasiou G, Taouxidou P, Mitsiou M et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: A systematic review and meta-analysis. Calcif Tissue Int. 2020;107(5):453–63. doi: 10.1007/s00223-020-00742-y.
3. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–68. doi: 10.1038/nature10777.
4. Aydin S. Three new players in energy regulation: Preptin, adropin and irisin. Peptides. 2014;56:94–110. doi: 10.1016/j.peptides.2014.03.021.
5. Li Q, Jia S, Xu L, Li B, Chen N. Metformin-induced autophagy and irisin improves INS-1 cell function and survival in high-glucose environment via AMPK/SIRT1/PGC1α signal pathway. Food Sci Nutr. 2019;7(5):1695–703.doi: 10.1002/fsn3.1006.
6. Perakakis N, Triantafyllou GA, Fernandez-Real JM, Huh JY, Park KH, Seufert J, Mantzoros CS. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324–37. doi: 10.1038/nrendo.2016.221.
7. Martinez M, Camarillo R, Garduno G. Irisin a novel metabolic biomarker: Present knowledge and future directions. Int J Endocrinol. 2018;2018:7816806. doi: 10.1155/2018/7816806.
8. Yuksel Ozgor B, Demiral I, Zeybek U, Celik F, Buyru F, Yeh J, Bastu E. Effects of irisin compared with exercise on specific metabolic and obesity parameters in female mice with obesity. Metab Syndr Relat Disord. 2020;18(3):141–45. doi: 10.1089/met.2019.0083.
9. Xin C, Liu J, Zhang J, Zhu D, Wang H, Xiong L et al. Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int J Obes (Lond). 2016;40(3):443–51. doi: 10.1038/ij 15.199.
10. Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. J Diabetes Investig. 2019;10(2):399–407. doi: 10.1111/jdi.12888.
11. Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(2):581–88. doi: 10.1111/dom.14255
12. Love KM, Liu J, Regensteiner JG, Reusch JEB, Liu Z. GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. J Diabetes. 2020;12(7):488–98. doi: 10.1111/1753-0407.13045.
13. Lisco G, Disoteo OE, De Tullio A, De Geronimo V, Giagulli VA, Monzani F et al. Sarcopenia and diabetes: A detrimental liaison of advancing age. Nutrients. 2023;16(1):63. doi: 10.3390/nu16010063.
14. Дедов И.И., Шестакова М.В., Майоров А.Ю., Мокрышева Н.Г., Андреева Е.Н. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(S2):1–157. doi: 10.14341/DM13042.
15. Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168–76. doi: 10.2337/dc13-2759.
16. Dungan KM, Povedano ST, Forst T, Gonzalez JG, Atisso C, Sealls W, Fahrbach JL. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–57. doi: 10.1016/S0140-6736(14)60976-4.
17. Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): A randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849–58. doi: 10.1111/dom.12479.
18. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG et al.; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–86. doi: 10.2337/dc10-2415.
19. Diabetes mellitus: A major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation. 1999;100(10):1132–33. doi: 10.1161/01.cir.100.10.1132.
20. Liu S, Cui F, Ning K, Wang Z, Fu P, Wang D, Xu H. Role of irisin in physiology and pathology. Front Endocrinol (Lausanne). 2022;13:962968.doi: 10.3389/fendo.2022.962968.
21. Guo M, Yao J, Li J, Zhang J, Wang D, Zuo H et al. Irisin ameliorates age-associated sarcopenia and metabolic dysfunction. J Cachexia Sarcopenia Muscle. 2023;14(1):391–405. doi: 10.1002/jcsm.13141.
22. Pacifico J, Geerlings MAJ, Reijnierse EM, Phassouliotis C, Lim WK, Maier AB. Prevalence of sarcopenia as a comorbid disease: A systematic review and metaanalysis. Exp Gerontol. 2020;131:110801. doi: 10.1016/j.exger.2019.110801.
23. Anagnostis P, Gkekas NK, Achilla C, Pananastasiou G, Taouxidou P, Mitsiou M et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: A systematic review and meta-analysis. Calcif Tissue Int. 2020;107(5):453–63. doi: 10.1007/s00223-020-00742-y.
24. Qiao YS, Chai YH, Gong HJ, Zhuldyz Z, Stehouwer CDA, Zhou JB, Simo R. The association between diabetes mellitus and risk of sarcopenia: Accumulated evidences from observational studies. Front Endocrinol (Lausanne). 2021;12:782391. doi: 10.3389/fendo.2021.782391.
25. Ida S, Kaneko R, Imataka K, Murata K. Association between sarcopenia and renal function in patients with diabetes: A systematic review and meta-analysis. J Diabetes Res. 2019;2019:1365189. doi: 10.1155/2019/1365189.
26. Wannarong T, Sukpornchairak P, Naweera W, Geiger CD, Ungprasert P. Association between diabetic peripheral neuropathy and sarcopenia: A systematic review and meta-analysis. Geriatr Gerontol Int. 2022;22(9):785–89. doi: 10.1111/ggi.14462.
27. Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F et al. Prevalence and risk factors of sarcopenia in patients with diabetes: A meta-analysis. J Clin Endocrinol Metab. 2022;107(5):1470–83. doi: 10.1210/clinem/dgab884.
28. Iwai S, Kaji K, Nishimura N, Kubo T, Tomooka F, Shibamoto A et al. Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice. Biochim Biophys Acta Mol Basis Dis. 2023;1869(7):166770. doi: 10.1016/j.bbadis.2023.166770.
29. Xiang J, Qin L, Zhong J, Xia N, Liang Y. GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway. Diabetes Metab Syndr Obes. 2023;16:2433–46. doi: 10.2147/DMSO.S425642.
30. Guarnotta V, Bianco M, Vigneri E et al. Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2021;31(11):3193–201. doi: 10.1016/j.numecd.2021.07.015.
Review
For citations:
Gusenbekova D.G., Ametov A.S., Korotkova T.N. Efficacy and safety of dulaglutide in patients with type 2 diabetes and obesity. FOCUS. Endocrinology. 2025;6(3):6-11. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-3-02
Views:
221
JATS XML
Email this article 